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Background: The incidence of occupational hand eczema is approximately 0.32 per 1,000 person years. The
burden of the disease is high, as almost 60% has eczema-related sick leave during the first year after notification,
and 15% are excluded from the workforce 12 years after disease onset. New treatments and prevention strategies
are needed.
Methods/Design: Trial design: The PREVEX trial is a randomised, parallel-group, superiority trial.
Participants: All individuals from the Capital Region of Denmark and Region Zealand with a suspected occupational skin
disorder notified to the National Board of Industrial Injuries between June 2012 and December 2013 are invited to
participate in the trial. Inclusion criteria are: self-reported hand eczema and informed consent. Exclusion criteria are: age
<18 years or >65 years; permanent exclusion from the workforce; inability to understand the Danish language; any
serious medical condition; and lack of written informed consent. We plan to randomise 742 participants. Interventions:
The experimental intervention is an educational course in skin-protective behaviour and written information about skin
care related to the participants' specific occupation. Also, a telephone hotline is available and a subgroup will be of-
fered a work-place visit. The experimental and the control group have access to usual care and treatment. All partici-
pants are contacted every eighth week with questions regarding number of days with sick leave or other absence
from work. 12 months after randomisation follow-up is completed. Objective: To assesses the effect of an educational
course versus treatment as usual in participants with newly notified occupational hand eczema. Randomisation: Partici-
pants are centrally randomised according to a computer-generated allocation sequence with a varying block size con-
cealed to investigators. Blinding: It is not possible to blind the participants and investigators, however, data obtained
from registers, data entry, statistical analyses, and drawing of conclusions will be blinded. Outcomes: The three co-
primary outcomes, assessed at 12 months, are: total number of self-reported days with sick leave; health-related qual-
ity of life; and subjective assessment of hand eczema severity. Explorative outcomes are: self-reported eczema-related
sick leave, absence from work registered by the DREAM-register and by self-report, risk behaviour, knowledge of skin
protection and performance management (self-efficacy; and self-evaluated ability to self-care).
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Discussion: The PREVEX trial will be the first individually randomised trial to investigate the benefits and harms of
group-based education in patients with newly notified occupational hand eczema.
Trial registration: ClinicalTrials.gov Identifier: NCT01899287
Keywords: Occupational hand eczema, OHE, Occupational contact dermatitis (OCD), Prevention, Work related,
InterventionBackground
Occupational hand eczema is the most frequently recog-
nised occupational disease in Denmark [1]. The inci-
dence is approximately 0.32 per 1,000 persons in the
total population [2], and the numbers are comparable in
most of the industrialised world [3].
In 2011, the Danish National Board of Industrial Injur-
ies recognised a total of 1,395 individuals with occupa-
tional skin diseases, and the large majority of these
patients (> 90%) had occupational hand eczema.
Hand eczema affects mainly young people as 1/3 has
onset of disease before the age of 20 years [2]. The life-
time prevalence is almost twice as high in women as it is
in men [1]. This is mainly due to women’s higher expos-
ure to wet work, occupationally as well as privately,
which are well known risk factors [3]. Other aggravating
factors are atopic dermatitis and contact allergy [1].
Hand eczema often takes a chronic course. A Swedish
follow-up study reported active eczema 12 years after on-
set of disease in 72% of the sample of patients and found
that 15% had been excluded from the work force [4]. In a
Danish study, similar data were reported [5,6]. During a
one-year period, 20% of patients with notified hand ec-
zema had sick leave for more than five weeks due to skin
disease, and 20% to 25% had loss of job (examined in the
time span between notification and recognition). 57% had
sick leave because of skin disease during the first year after
notification. These data show that the burden of the dis-
ease is high in a personal as well as in a socio-economic
context [7]. The number of persons with occupational
hand eczema has remained unchanged despite public ini-
tiatives to reduce exposures to harmful allergens [8].
Current treatment and prevention
In Denmark, there is no standard for secondary preven-
tion of occupational hand eczema. However, operational
guidelines for the diagnostic evaluation and treatment of
hand eczema exist [9]. The guidelines recommend that
advice should be given about personal protective equip-
ment (e.g., gloves), and skin care with moisturisers.
In Germany, a course is offered to all health-care
workers with occupational skin disease [10]. Persons
with notified skin diseases are immediately after the no-
tification invited to attend a two-day skin-protection
course. The course is organised in cooperation withdermatologists, allergologists, occupational medicine
specialists, hygiene specialists, and other staff members.
The course includes a medical examination by a derma-
tologist, topics on medical history, atopic disposition,
further diagnostics, therapy, skin protection, and an as-
sessment of the patient’s ability to remain in her/his job.
All findings by the physician are forwarded to the au-
thorities, and they are the basis for the further treatment
possibilities offered to the patient. This includes, in the
most severe cases, initiation of a 3-weeks inpatient treat-
ment programme. An observational study found that the
course improved skin care and skin-protection behav-
iour, hand eczema, and quality of life one year after the
course compared to before the course [11].
Clinical data
A systematic review of randomised trials and controlled
trials from 2010 assessed prevention programmes com-
pared to no intervention or treatment as usual in partici-
pants with hand dermatitis [12]. The reviewers included
seven trials. No meta-analyses were conducted, as the
reviewers assessed the trials to be too heterogeneous
with regard to populations, interventions, control
groups, and outcome measures. Overall, the reviewers
concluded that there was moderate evidence for the ef-
fect of preventive programmes on occurrence of hand
dermatitis and adherence to preventive measures, and
low evidence for improving clinical outcomes and self-
reported outcomes. Furthermore, none of the included tri-
als had ‘low risk of bias’ in all assessed domains, and the
review was restricted to publications in English, with a
high risk of publication bias. Also, the review did not dis-
tinguish between primary and secondary prevention trials.
We therefore conducted an updated search for rando-
mised and controlled trials in hand eczema patients in
December 2012 in the PubMed database. From this
search, we identified two randomised trials with focus
on secondary prevention by educational programmes in
hand eczema patients. Both of these trials applied indi-
vidual randomisation. One trial found that an individual
intervention among health-care workers with self-
reported hand eczema increases the participants’ use of
preventive measures and improves hand eczema and
quality of life compared with no intervention [13,14].
The other trial [15,16] found that patients with HE
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multidisciplinary team with respect to clinical severity,
but the intervention did not significantly influence qual-
ity of life (QoL) or sick leave.
We identified nine other trials with focus on secondary
prevention of hand eczema by educational programmes in
various working groups. Overall, they have found a positive
effect of secondary skin protection programmes on occupa-
tional hand eczema in patients from different professions
such as health care workers [17-23], gut cleaners [24], and
workers in the cheese-dairy industry [25]. However, since
these studies did not focus on hand eczema patients, but
on a mixture of healthy workers and workers with hand ec-
zema, the results are not directly comparable. Also, most of
these studies were cluster-randomised with a high risk of
systematic errors (that is risk of overestimation of benefits
and underestimation of harms) and random errors (that is
play of chance), and two studies focused mostly on use of
emollients [18,21]. In addition to the published trials we
found one design article on a randomised trial [26]. This
trial aims to investigate a guidance programme in self-
management chronic hand eczema. The trial is ongoing
and results are thus yet unknown.
Overall, randomised clinical trials and a systematic review
of the randomised clinical trials indicate a positive effect of
prevention programmes for patients with occupational
hand eczema. However, we still lack information from large
randomised clinical trials with a low risk of bias on the ef-
fect of a low-cost group-based education. The PREVEX trial
will be the first individually randomised trial to investigate
the benefits and harms of group-based education in pa-
tients with newly notified occupational hand eczema.
Objectives
The objectives of the PREVEX trial are to investigate
the benefits and harms of a complex intervention con-
sisting of:
A. Group education on general skin-protective
behaviour.
B. Job-specific counselling on work-related
skin-protective behaviour, which might extend to a
work-place visit.
C. Social guidance related to occupational hand
eczema.
D. Telephone hotline for work- and patient-related
problems, maintained by nurse or medical doctor.
Methods
Trial design
The PREVEX trial is a randomised, parallel-group, su-
periority trial without blinded outcome assessment of
the primary outcomes, but several of the secondary out-
comes will be blinded (see below) (Figure 1).Setting and selection of participants
Participants are recruited from the National Board of In-
dustrial Injuries files. These files include information on
all notified industrial injuries in Denmark. All individ-
uals from Region Zealand and the Capital Region of
Denmark (except the island of Bornholm) with a sus-
pected skin-related industrial injury notified between
July 2012 and December 2013 will be invited to partici-
pate in the trial. The trial invitation will be sent along
with the postal questionnaire, participant information
sheet, an informed consent form, and a pre-paid return
envelope. All individuals will be encouraged in the invi-
tation to contact the investigators for further informa-
tion or if they wish for an individual meeting with verbal
information. Individuals who return the questionnaire
will be eligible for the PREVEX trial, if they comply with
the following inclusion and exclusion criteria.
Inclusion criteria
 Living in Denmark.
 Self-reported hand eczema, i.e., individuals
answering ‘yes’ in the questionnaire to the question
‘have you or have you had hand eczema?’
 The questionnaire is sufficiently filled in with
respect to ‘severity of hand eczema’ and ‘profession’.
 Written informed consent.
Exclusion criteria
 Age below 18 years or above 65 years.
 Permanently excluded from the workforce.
 Inability to understand the Danish language
sufficiently to benefit from the course.
 Any serious medical condition which, in the opinion
of the investigator, may interfere with the evaluation
of the results.
 Lack of written informed consent.
Participant withdrawal and discontinuation of
participants
The participants are free to withdraw their informed
consent from the trial at any time without effecting fu-
ture treatment or their case processing in the National
Board of Industrial Injuries. If a participant wishes to
withdraw his or hers consent, they will be contacted and
asked to specify which aspects of the trial they wish to
withdraw from: participation in the experimental interven-
tion, participation in follow-up interviews and answering
the questionnaires, use of follow-up data collected from
national databases, or complete withdrawal from trial, i.e.,
use of already collected data the analyses.
All participants who enter the trial will be accounted for
in the publication of the results. Participants who fail in
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Figure 1 Trial flowchart.
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offered a new course. Participants who cannot be reached
during the follow-up period will be contacted and encour-
aged to resume contact. Participants who do not return the
follow-up questionnaire will be contacted and a letter will
be sent containing a questionnaire on reasons for drop out.
Randomisation
When the participants have returned the questionnaire
and they fulfil all inclusion criteria and none of the ex-
clusion criteria, they are randomised. The investigatorcontacts the Copenhagen Trial Unit (CTU) by tele-
phone, and the CTU staff will perform the allocation
according to data entered in a computer system.
Participants will be randomised individually 1:1 to the ex-
perimental group versus the control group centrally ac-
cording to a computer-generated allocation sequence with
a varying block size concealed to investigators. Random-
isation will be stratified according to age (up to 39 years,
or older than 40 years); self-reported hand eczema severity
(‘none and light’ or ‘moderate, severe, and very severe’);
and profession (‘healthcare’, ‘kitchen or cleaning staff ’,
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sions’). After the allocation, the investigators will inform
the participants about the allocation by telephone.
Blinding
It is not possible to blind the participants or investiga-
tors with respect to treatment allocation. However, data
entry from the questionnaires, outcome assessment re-
garding absence from the work force (the eight week
follow-up telephone calls, data from the DREAM regis-
ter, and data from other national registers), statistical
analyses, and conclusions will all be blinded.
Trial duration
The inclusion period is estimated to be 18 months. The
first participant was included in 13 July 2012, and we ex-
pect inclusion of the last participant in December 2013.
Self-reported data on absence from work will be con-
tinuously collected (every eighth week). Follow-up for
the individual participants will be 12 months after inclu-
sion and is expected to be completed in December 2014.
Experimental group
The experimental intervention consists of four compo-
nents, A to D, as well as usual care, E:
A. Group education on general skin-protective
behaviourTable 1 The ten recommendations regarding how to
avoid hand eczema [27]
1. Use gloves when beginning wet work tasks.
2. Gloves must be used as long time as necessary but as short
as possible.
3. Protective gloves should be intact and clean and dry inside.
4. When protective gloves are used for more than 10 minutes, cotton
gloves should be worn underneath.
5. Wash hands in lukewarm water and dry them well.
6. Alcohol-based disinfections should be used instead of soap when
the hands are not visibly dirty.
7. Do not wear rings at work.
8. Use a moisturiser with a high fat content and no perfume.
9. Moisturisers should be applied all over the hands, including the
webs, finger tips and dorsal aspects.
10. Take care also when doing domestic work. Use protective gloves
for dish washing and insulating gloves in the winter.Participants in the experimental group will
participate in a two-hour course. One or two
courses per week will be available. A secretary or
nurse will arrange booking with the participants allo-
cated to the experimental group. A maximum of 12
participants per course is expected. The courses will
be conducted by two investigators. Participants can
choose between an evening and a daytime course.
The group education will comprise basic knowledge
about the skin, the development of eczema, and
recommendations for skin protection and care. The
recommended skin protection programme has been
summarized into ten recommendations in Denmark
(Table 1). These ten recommendations will be the
basis of the education [27].
There will be practical demonstrations in hand
washing and use of disinfectants, use of moisturiser,
and use of different types of gloves (cotton, rubber,
nitrile, vinyl gloves, and gloves with and without
fingers).
B. Job-specific counselling on work-related skin-protective
behaviour, which might extend to a work-place visit
The job-specific counselling will comprise specific
recommendations for skin care in different occupa-
tions. For ten occupations with some of the highest
numbers of recognised occupational hand eczemapatients in 2010 [28], the information will be stan-
dardised and written information will be available
(Table 2). In case of other occupations, or with spe-
cific problems, a work visit will be offered and ar-
ranged. A doctor or a nurse will undertake the visit,
and counselling will be based on this.
C. Social guidance related to occupational hand eczema
The social guidance related to the occupational hand
eczema will include information on rules and rights
during an occupational injury. This will also include
information about the options for help from workers
compensation or social welfare in case of job-loss or
change.
D. Telephone hotline
An occupational nurse will provide assistance via
telephone about questions and social problems.
The telephone hotline will mainly include
information already given at the course, but may be
more specifically given to the particular individual.
The purpose of the hotline is to repeat information
from the course, which may have been forgotten or
misunderstood, and to guide the participant in case
of questions related to the social situation related
to the occupational skin disease. It is the intention
that the hotline shall generally function as a
‘helping hand’.
E. Treatment and care as usual
The experimental group will have access to usual
treatment and care (see below).Control group
The control group will not have access to the components A
to D encompassing group education, the profession specific
information, the social guidance, and the telephone hotline,
Table 2 Ten occupations where job-specific
recommendations for skin care is available [28]
Occupation Number of recognised
occupational hand
eczema patients in 2010
Health care workers, care workers not
hospital
456





Mechanics, machine operator, metal worker 113
Sales assistant 41
Dentist assistant 39
Gardener, agricultural worker 37
Fisker et al. BMC Dermatology 2013, 13:16 Page 6 of 11
http://www.biomedcentral.com/1471-5945/13/16but they have access to usual treatment and care with their
general practitioner and dermatologist (component E).
Usual treatment and care available to both intervention
groups
After notification to the National Board of Industrial In-
juries, a medical examination including allergy testing of
the patient will take place. This will be either as a spe-
cialist’s certificate performed by a specialist in dermatol-
ogy, or an examination in a dermatological department
in a hospital. The decision to recognise or reject the pa-
tient as having an occupational disease will be based on
data from this investigation.
The participants in both intervention groups have ac-
cess to the usual care and treatment with the general
practitioner and dermatologist. Such care will be regis-
tered via central registers.
Concomitant medication and treatment
All medication and other treatment are permitted during
the trial. We will register use of topical corticosteroids




Participants fill in a questionnaire regarding basic demo-
graphic factors, self-reported level of eczema severity
using a photographic guide [29], health-related quality of
life (the Dermatology Life Quality Index) [30], level of
knowledge concerning prevention of hand eczema, oc-
cupational exposure and exposure during leisure time,
strength of coping, and performance management. The
questionnaires are returned by mail. Data will be entered
into Statistical Analysis Software (SAS). This will bedone by scanning and where that is not possibly, manu-
ally, by external assistants.
Participation in the experimental intervention
Participation in the course will be registered in paper
record forms by the investigators and later manually
registered in SAS.
Follow-up period, from inclusion to 12 months after inclusion
Data on absence from workforce will be collected every
eight weeks, by telephone call, e-mail, text message or
any other chosen form of media by a blinded investiga-
tor, for one year in the intervention group and in the
control group. The data will be registered directly in
paper record forms by a nurse. Absence will be cate-
gorised by participants as: total sick leave; eczema-
related sick leave; absence from work for other reasons
(child care during illness, etc.); unemployment; and
other reasons. Later these data will be entered into SAS
by the external assistants.
End of follow-up, 12 months after inclusion
Participants fill in a follow-up questionnaire regarding
self-reported level of eczema severity using a photo-
graphic guide [29], health-related quality of life (the
Dermatology Life Quality Index) [30], level of knowledge
concerning prevention of hand eczema, occupational ex-
posure and performance management. The follow-up
questionnaire will be distributed by mail to all partici-
pants and when returned, entered into SAS by scanning
and where that is not possibly, manually, by external as-
sistants. Data on absence from the work force for a
period longer than 28 days will be collected from the
DREAM register [31]. Further, data regarding potential
effect modifiers, i.e., the participants’ use of topical corti-
costeroids will be collected from The Danish National
Database of Reimbursed Prescriptions [32], and visits
with a dermatologist will be retrieved from The National
Health Insurance Service Registry [33]. Data from both
national registers will be collected using the unique Da-
nish Civil Registration Number.
Data management
Data is handled and recorded in paper record forms and
kept in records marked with investigator number, pa-
tient identification number, and name of region. The
data on absence from work are handled and recorded in
participant record forms and kept in records marked
with investigator number, patient identification number,
name of region, and time of assessment. Paper question-
naires collected at follow up (12 months) is kept in other
records marked with investigator number, name of re-
gion, and time of assessment. After follow up all the rec-
ord forms from each participant will be collected in
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files or participant record forms will be documented
with date and signature of the investigator.
Data from the records will be registered electronically in
SAS for statistical analyses. This will be done partly by scan-
ning and partly manually by external assistants. Records will
be archived for at least five years after end of trial.
Quality control and quality assurance
To ensure the trial is conducted and reported in compli-
ance with this protocol, the data are monitored intern-
ally. The investigators monitor the data and check for
systematic errors. All data are registered in paper record
forms and kept at an investigator site file available only
for the investigators. Around 5% of the data is moni-
tored to assess consistency between the paper record
forms, electronically registered data, and signed consent
forms. Data are handled with confidentiality.
Primary outcomes
The PREVEX trial has three co-primary outcomes:
 Total sick leave; measured as self-reported total
number of days with sick leave during the trial
period.
 Health-related quality of life; measured as points
scored in the Dermatology Life Quality Index
(DLQI) at 12 months after inclusion [30].
 Subjective assessment of hand eczema severity;
measured by use of a photographic guide at
12 months after inclusion [29].
Explorative outcomes
The following outcomes will be assessed as explorative,
as there is insufficient information to conduct power
calculations.
 Eczema-related sick leave; measured as self-
reported total number of days with eczema-related
sick leave during the trial period.
 Absence registered by the DREAM-register; only
absence for more than 28 days from workplace is
registered here. This will be done at 12 months after
randomisation. We will measure absence from work
because of sick leave for more than 28 days, yes or no.
 Absence, self-reported total number of days with
absence during the trial period.
 Behaviour measured as number of points achieved
in a questionnaire concerning both occupational and
private risk behaviour at 12 months after
randomisation.
 Knowledge of skin protection measured as
numbers of points achieved in a multiple choice
questionnaire at 12 months after randomisation. Performance management at 12 months after
randomisation of the participant measured by the
number of points achieved in:O Self-efficacy [34]; and
O Self-evaluated ability to self-care.Risks and benefits
We do not expect any risks for the participants, except
the risks following transportation to and from the educa-
tional site. The intervention is of educational character,
no drugs or medical devices will be used. During the
course there will be a nurse and/or medical doctor
present. In case of adverse advents, the investigators will
act according to their professions’ current ethical and
professional standards.
If the intervention proves effective, benefits such as lower
severity of occupational hand eczema, less sick leave, and
diminished risk of exclusion from the work force are ex-
pected in the experimental group. A general improvement
in health-related quality of life is also expected.Ethical considerations
The intervention is of educational character. The intention
is to improve knowledge, behaviour, and consequently
disease severity and absence from work, by an educa-
tional programme. No drugs or risk-full testing are used
in the trial.
Medical treatment of the patients hand eczema will
not be a part of this trial, and there will be no difference
in access to the medical treatment in the experimental
and control group.
Furthermore, as there is no existing evidence on the
effect of more expensive interventions in this patient
group, it is considered good ethical conduct to perform
the described trial with a control group who are offered
‘treatment as usual’.
The main results of the trial will be presented to the
included participants in a newsletter, where there will be
references to any data published in medical journals.Trial conduct
The PREVEX trial will be conducted in compliance with
the trial protocol and the Helsinki Declaration in its lat-
est form. The protocol has been submitted for review to
the Regional Ethics Committee for the Capital Region
(journal number: H-1-2012-053), who replied that the
PREVEX trial is not a ‘biomedical trial’, as no medicinal
interventions take place, and accordingly a formal review
by the Ethics Committee is not necessary. The trial has
been approved be the Danish Data Protection Agency
(journal number BBH-2011-33), and it has been registered
on www.clinicaltrial.gov (identifier: NCT01899287).
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Calculations were made using ‘PS: Power and Sample
Size Calculation’ version 3.0.14 [35]. A sample size was
calculated for each of the three co-primary outcomes
and the largest of the three sample sizes was chosen as
the target sample size. To adjust for multiple testing, we
divided the risk of type I error, 5%, by three, and we thus
used a risk type I error of 1.67% and a risk of type II
error of 20% (80% power). This calculation is based on
the assumption that Holm’s procedure [36] will be used
to adjust alpha (5%) to ensure that the family wise type I
error will not exceed 5%. Holm’s procedure works as fol-
lows: let p(1), p(2) and p(3) be the observed P values
where p(1) < p(2) < p(3) and H(1), H(2) and H(3) are the
corresponding hypotheses. The hypotheses are tested in
that order. At the J’th step H(J) is rejected if P(J) < 0.05/
(3 – J +1). Otherwise H(J) and all other untested hy-
potheses are accepted and the procedure stops. Since we
cannot know in advance which of the three outcomes
will be associated with the smallest P value, the largest
of the three sample sizes is chosen to secure that the
power will be at least 80%.
For the continuous variable ‘total sick days’, we used
unpublished data from the Working Environment Co-
hort (Arbejdsmiljøkohorten) from the National Research
Centre for the Working Environment (www.arbejdsmil-
joforskning.dk) to estimate the sample size. In this co-
hort of 9,786 healthy individuals, the mean number of
sick days in year 2010 was 6.74 (95% confidence interval
(CI) 6.32 to 7.15). We expect a higher degree of sick
days in the PREVEX population, and we estimate that
the mean number of total sick days in the PREVEX trial
will be higher, probably about 20 sick days per year.
From the data above, we calculated the standard devi-
ation (SD) using this formula:
SD ¼ ﬃﬃﬃﬃNp  95%CI upper limit − 95%CI lower limit
3:92
⇓




To detect a difference in total sick days of 5 days (25%
risk reduction), we need 742 participants (371 partici-
pants in each intervention group) (Table 3).
For the DLQI, we used a standard deviation of 4.8
points [37]. In order to detect a difference between the
two intervention group of 1.2 points (corresponding to
25% of the standard deviation), we will need to include
672 participants (336 participants in each intervention
group). By inclusion of 742 participants, the risk of type
II error will be reduced to 15.7% (power of 84.3%).For the subjective assessment of hand eczema severity,
prior data indicate that the proportion of participants
with moderate to severe symptoms is 60% [38]. If the
proportion of participants with moderate to severe
symptoms can be reduced to 48% (relative risk reduction
of 20%) in the experimental group, we need to include
720 participants (360 participants in each intervention
group). By inclusion of 742 participants, the risk of type
II error will be reduced to 18.6% (power of 81.4%).
In total, we will include 742 participants in the PRE-
VEX trial, which was the maximum number of partici-
pants needed according to the three calculations.Expected participant recruitment
A former study using a questionnaire on patients with
occupational skin disease conducted in 2002 achieved a
high response rate of 82% [6]. According to statistics
from the National Board of Industrial Injuries, approxi-
mately 1,000 individuals reported a skin-related indus-
trial injury in 2010 in Region Zealand and in the Capital
Region of Denmark. Therefore, we conservatively as-
sume that we will be able to complete recruitment of
the 742 participants within 18 months.Plan for statistical analyses
Analysis of the three primary outcomes
Types of analyses Depending on the specific type of
outcome measure, one of three types of regression ana-
lyses will be applied.
 Type 1 includes a rate (count of events over period
of observation (12 months according to plan). Using
the countreg procedure (SAS 9.3), the Poisson
model, and the negative binomial model, the rate
will be compared by testing for overdispersion and
comparing the average predicted count probabilities
and the observed proportions. The best model will
be used to analyse data.
 Type 2 includes a continuous outcome measure. The
general linear univariate model will be used.
 Type 3 The ordinal outcomes will be analysed using
the proportional odds model where the intervention
group indicator is included as a co-variate provided
the P value of the score test of the proportional odds
assumption is ≥ 0.05.
All of the above analyses will include the three protocol
specified stratification variables (age groups, self-reported
hand eczema severity, and profession) as covariates in
addition to the intervention indicator and baseline value if
available. If the assumptions of an analysis are seriously vi-
olated, a non-parametric test will be used.
Table 3 Sample size estimations
Outcome Minimum relevant difference Risk of type I
error




Total sick days 5 days (SD* 21 days) 1.67% 20% 742
DLQI† 1.2 points (SD 4.8 points) 1.67% 20%‡ 672
Subjective assessment of hand
eczema severity
20% risk reduction from 60% event rate in
the control group
1.67% 20%§ 720
*Standard deviation of the mean.
†Dermatology Life Quality Index.
‡Will be reduced to 15.7% when 742 participants are included.
§Will be reduced to 18.6% when 742 participants are included.
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values exceeds 5% for any of the three outcomes or Lit-
tle’s test is significant (p < 0.05), multiple imputations
(MI) will be used (SPSS version 17 or later).
Sensitivity analyses For each of the three outcomes,
two types of imputations will be conducted. 1) Missing
values in one group will be imputed by the maximum
value observed in the material and missing values in the
other group will be imputed by the minimum value ob-
served, and 2) vice versa. For each type of imputation
the two groups will be compared to obtain the spectrum
of potential bias.
Multiplicity The three P values corresponding to the
null hypotheses of the success criterion will be adjusted
using Hommel’s procedure [39]. Hommel’s procedure
could not be assumed in the sample size calculation
since the level of significance to be used cannot be
known in advance and therefore the adjustment of
alpha could not be specified. However, Hommel’s pro-
cedure is uniformly more powerful than Holm’s pro-
cedure [36]. So the reduction of the level of significance
will be less than or equal to that used were the Holm
procedure to be used.
Exploratory analyses
The exploratory analyses include regression analyses of
continuous and rate data observed 12 months following
randomisation. They are all similar to the above de-
scribed analyses. In addition, every 8 weeks during the
first 40 weeks and then at week 52 following the ran-
domisation the rate of sick leave is calculated. The six
rates are referred to as rate-I (I = 1 to 6) in the following
where we refer to the above six periods with rate-1 being
the rate observed during the first 8 weeks, rate-2 the rate
observed during week 9 to 16 following randomisation,
etc. The rate is defined as the number of days with sick
leave divided by the number of days of observation.
Using the generalised linear mixed model with repeated
measures we want to study rate as a function of time T,
the intervention indicator, and the covariates where Tvaries from 1 corresponding to period 1 (first 8 weeks)
to 6 (last 12 weeks) and rate = rate-I for T = I.
Trial organisation
The trial will take place at Bispebjerg Hospital in the
Capital region of Denmark and at local hospitals where
suitable in Region Zealand. The investigators are respon-
sible for the protocol, conducting of the trial, and all
other aspects involved.
Finance and insurance
The trial is financed by job-specific who covers all ex-
penses related to the trial (grant number: 20.2010-09).
The participants in the trial are covered by the Patients
Insurance Association under the existing rules as the
trial is performed under the authority of Bispebjerg
Hospital.
Publication plan
The trial results will be published in international der-
matological, medical and occupational scientific journals
and presented in national and international dermatology
and occupational medicine conferences. The investiga-
tors will follow the rules and guidelines of the Inter-
national Committee for Medical Journal Editors (ICMJE)
for authorship [40].
Discussion
The prevalence of occupational hand eczema is high with
large consequences at the personal and societal level. The
ultimate aim of the PREVEX trial is to contribute to the
development of new strategies for secondary prevention
in patients with occupational hand eczema.
The timing in this trial is unique. Notification of an
occupational injury often brings the individual in an in-
secure situation concerning the affiliation with the work-
force. The intervention is delivered immediately after
notification, which gives the best conditions to minimise
these elements. The intervention in PREVEX is general
as well as simplistic. This will heighten the possibility to
determine the actual effectors, if any, in the intervention.
Furthermore, the intervention is low-cost and thus more
implementable in society.
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population will be heterogeneous regarding the severity
of hand eczema, participants’ occupation, and previous
treatment ranging from none to care in a dermatological
setting. Accordingly, findings of the trial should have
generalisability.
The trial has been designed in order to minimise the risks
of systematic errors [41-43] and the risks of random errors
[43]. Systematic errors have been sought reduced by central
randomisation stratified for prognostic factors [41-43].
Blinding is used whenever possible and data will be ana-
lysed according to the intention-to-treat principle. We are
aware that some outcomes are at risk of being assessed
with some bias, as they are not possible to blind [41-43].
The risk of random error has been reduced by choos-
ing the largest of three possible sample size estimations.
Any significant differences regarding the exploratory
outcomes shall be interpreted with caution as they may
be due to random errors.
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